ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other Events

Item 8.01 Other Events

On December8, 2016, ContraVir Pharmaceuticals,Inc. (the Company)
issued a press release providing new insights into the mechanism
of action of its hepatitis B (HBV)-optimized cyclophilin
inhibitor CRV431, showing that it effectively blocks a critical
interaction between HBV X protein (HBx) and host cyclophilin A,
with nanomolar potency.

The press release is attached as Exhibit99.1 to this report on
Form8-K and is incorporated herein by reference.

Item9.01
FinancialStatementsandExhibits

(d)Exhibits

About ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) Recent Trading Information

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) closed its last trading session down -0.02 at 1.96 with 364,348 shares trading hands.